Genprex Inc. priced its IPO of 1,280,000 common shares at $5 apiece.

Network 1 Financial Securities Inc. is acting as the sole book-running manager for the offering which is expected to close on April 3.

The Austin, Texas-based company, which is developing a therapy for lung cancer, is listing on Nasdaq under the symbol 'GNPX.'

The IPO's underwriters can buy up to an additional 192,000 shares from the company.